Carbon monoxide ameliorates murine T-cell-dependent colitis through the inhibition of Th17 differentiation. (2nd December 2018)

• Record Type: Journal Article
• Authors: Takagi, Tomohisa; Naito, Yuji; Tanaka, Makoto; Mizushima, Katsura; Ushiroda, Chihiro; Toyokawa, Yuki; Uchiyama, Kazuhiko; Hamaguchi, Masahide; Handa, Osamu; Itoh, Yoshito
• Is Part Of: Free radical research. Volume 52:Number 11/12(2018)
• Page Start: 1328
• Page End: 1335
• Publication Date: 2018-12-02
• Subjects: Carbon monoxide -- colitis -- Th17 differentiation; Free radicals (Chemistry) -- Periodicals; Antioxidants -- Periodicals; Vitamin C -- Periodicals; Vitamin E -- Periodicals; 541.224
• DOI: 10.1080/10715762.2018.1470327
• Languages: English
• ISSNs: 1071-5762

Abstract

Abstract: Recent studies have identified carbon monoxide (CO) as a potential therapeutic molecule for the treatment of inflammatory diseases including intestinal inflammation. In the present study, we explored the efficacy and the mechanisms of action of CO-releasing molecule (CORM)-A1 in T-cell transfer induced colitis model in mice. In addition, the impact of CORM-A1 on the T helper (Th) cell differentiation was evaluated using naïve CD4 + T cells isolated from the spleens in Balb/c mice. The results showed that CORM-A1 conferred protection against the development of intestinal inflammation and attenuated Th17 cell differentiation. Hence, the observed immunomodulatory effects of CORM-A1 could be useful for developing novel therapeutic approaches for managing intestinal inflammation through the regulation of Th17 differentiation.